Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.

Date publication

décembre 2014

Journal

International journal of cardiology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Rossignol P, Zannad F, Pitt B,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25465821

Résumé

Numerous registries, including the most recent ESC Euro-observational registry, have reported a large and persistent gap between real-life practice in the use of life-saving evidence-based therapies (such as renin angiotensin antagonists, beta-blockers, mineralocorticoid receptor antagonists) and recommended practices in international guidelines. Although the use of multiple renin angiotensin aldosterone system-inhibitors is associated with the development of worsening renal function and hyperkalemia in patients with heart failure and reduced ejection fraction, increased efforts should be expended to initiate and maintain target doses of these agents so as to provide their benefits on mortality and hospitalizations for heart failure.

Mots clés

Aminobutyrates, pharmacology, Angiotensin Receptor Antagonists, pharmacology, Heart Failure, blood, Humans, Mineralocorticoid Receptor Antagonists, pharmacology, Randomized Controlled Trials as Topic, methods, Registries, Renin-Angiotensin System, drug effects, Stroke Volume, drug effects, Tetrazoles, pharmacology, Time Factors

Référence

Int. J. Cardiol.. 2014 Dec 20;177(3):731-3